Clinical Study
Solifenacin in Multiple Sclerosis Patients with Overactive Bladder: A Prospective Study
| | | Mean | Std. deviation | Std. error mean | value |
| Physical health | T1 | 25.9 | 19.7 | 4.8 | .191 | T2 | 27.4 | 22.9 | 5.6 |
| Role limitation (physical) | T1 | 25.0 | 35.4 | 8.6 | .173 | T2 | 32.4 | 35.1 | 8.5 |
| Role limitation (emotional) | T1 | 68.6 | 39.9 | 9.7 | .985 | T2 | 62.7 | 42.3 | 10.3 |
| Pain | T1 | 68.2 | 28.9 | 7.0 | .963 | T2 | 82.3 | 23.4 | 5.7 |
| Emotional well-being | T1 | 77.6 | 20.2 | 4.9 | .761 | T2 | 72.7 | 13.2 | 3.2 |
| Energy | T1 | 47.5 | 22.5 | 5.5 | .740 | T2 | 47.3 | 18.0 | 4.4 |
| Health perception | T1 | 36.2 | 18.2 | 4.4 | .041 | T2 | 37.4 | 15.6 | 3.8 |
| Social function | T1 | 54.9 | 12.9 | 3.1 | .631 | T2 | 58.8 | 12.3 | 3.0 |
| Cognitive function | T1 | 66.5 | 26.9 | 6.5 | .669 | T2 | 76.5 | 19.0 | 4.6 |
| Health distress | T1 | 67.1 | 21.2 | 5.1 | .517 | T2 | 69.4 | 21.4 | 5.2 |
| Sexual function | T1 | 44.6 | 31.3 | 7.6 | .203 | T2 | 51.0 | 32.1 | 7.8 |
| Change in health | T1 | 27.9 | 26.3 | 6.4 | .409 | T2 | 36.8 | 28.1 | 6.8 |
| Sexual satisfaction | T1 | 35.3 | 36.5 | 8.9 | .394 | T2 | 44.1 | 37.0 | 9.0 |
| Overall QoL | T1 | 58.2 | 13.2 | 3.2 | .725 | T2 | 57.7 | 12.0 | 2.9 |
| MS QoL54 (physical) | T1 | 44.3 | 15.3 | 3.7 | .446 | T2 | 48.4 | 15.4 | 3.7 |
| MS QoL54 (mental) | T1 | 68.8 | 20.6 | 5.0 | .863 | T2 | 67.7 | 17.5 | 4.2 |
| MS QoL54 (total) | T1 | 113.1 | 33.9 | 8.2 | .955 | T2 | 116.1 | 30.9 | 7.5 |
|
|